April 2018

  ETAP-Lab supports Plant Advanced Technologies in the development of its TEM1657 compound for the treatment of psoriasis   TEM1657 is a drug candidate discovered and optimized by Plant Advanced Technologies (PAT), a French Biotech company based in Vandœuvre-lès-Nancy. The preclinical studies perfomed with TEM1657 in ETAP-Lab's model of psoriasis in mice have demonstrated a similar efficacy to that of corticosteroids, the current reference of the market, but without their undesirable side effects. The results have been presented for the first time at the